Anti-WT1 monoclonal antibody (DCABH-811)
Mouse anti-Human WT1 monoclonal antibody for ELISA, WB, IHC-P
Online Inquiry Add to basket
Recombinant full length Human Wilms Tumor Protein.
IHC-P: 10 μg/ml.
*Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own experiment using appropriate negative and positive controls.
WT1; Wilms tumor 1; GUD; Wilms tumor protein; AWT1; WAGR
WT1 (Wilms Tumor 1) is a Protein Coding gene. Diseases associated with WT1 include denys-drash syndrome and wilms tumor susceptibility-5. Among its related pathways are Integrated Pancreatic Cancer Pathway and Regulation of Telomerase. GO annotations related to this gene include nucleic acid binding and sequence-specific DNA binding. An important paralog of this gene is EGR1. This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilms tumor. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described. In several variants, there is evidence for the use of a non-AUG (CUG) translation initiation codon upstream of, and in-frame with the first AUG. Authors of PMID:7926762 also provide evidence that WT1 mRNA undergoes RNA editing in human and rat, and that this process is tissue-restricted and developmentally regulated.
Regulation of Telomerase, organism-specific biosystem; Transcriptional misregulation in cancer, organism-specific biosystem; Transcriptional misregulation in cancer, conserved biosystem.
Have you cited DCABH-811 in a publication? Let us know
and earn a reward for your research.
Ordonez, NG; et al. The immunohistochemical diagnosis of mesothelioma - A comparative study of epithelioid mesothelioma and lung adenocarcinoma. AMERICAN JOURNAL OF SURGICAL PATHOLOGY 27:1031-1051(2003).
Barrett, AJ; Le Blanc, K; et al. Immunotherapy prospects for acute myeloid leukaemia. CLINICAL AND EXPERIMENTAL IMMUNOLOGY 161:223-232(2010).
Custom Antibody Labeling
We offer labeled antibodies using our catalogue antibody products and a broad range of intensely fluorescent dyes and labels including HRP, biotin, ALP, Alexa Fluor® dyes, DyLight® Fluor dyes, R-phycoerythrin (R-PE), at scales from less than 100 μg up to 1 g of IgG antibody.